Alembic Pharma gets USFDA’s approval for Dorzolamide Hydrochloride Ophthalmic Solution

13 Aug 2019 Evaluate

Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dorzolamide Hydrochloride Ophthalmic Solution USP, 2%.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Trusopt Ophthalmic Solution, 2%, of Merck Sharp & Dohme Corp. Dorzolamide Hydrochloride Ophthalmic Solution is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Dorzolamide Hydrochloride Ophthalmic Solution USP, 2% has an estimated market size of $35 million for twelve months ending December 2018 according to IQVIA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

991.00 -6.90 (-0.69%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.